What to expect from PEGS Europe 2023: Day 2
Drug Discovery World
NOVEMBER 9, 2023
Jorge Dias, PhD, Principal Scientist, Alchemab Therapeutics, on: ‘A patient-first approach to discover first-in-class antibody therapeutics’. Anthony Stajduhar, Director of Global Business Development, Business Development, Rapid Novor, on: ‘Antibody discovery dead ends and new approaches’.
52 
Let's personalize your content